Minoryx Therapeutics, winner of Senen Vilaró Prize, is a company specialized in the discovery and development of new drugs to treat rare diseases, which have a high socioeconomic cost for both the patients and families, and national health systems. In 2015, the University of Barcelona spin-off closed a round of funding valued at 19,4 million euros, the highest round reached by a biotec in Catalonia up to that moment, led by Ysios Capital and with the participation of Caixa Capital Risc, Health Equity and international investors such as Roche Venture Fund, Kurma Partners and Chiesi Ventures.

With this funding, Minoryx expanded its team to promote the R&D area and started stage 1 clinical studies of the drug MIN-102 for the treatment of Adrenoleukodystrophy (X-ALD), a neurodegenerative disease with a severe prognostic which affects one out of 17.000 births. At this moment there is no drug treatment for this minority disease and the only alternative is the bone marrow transplant.

The company, moreover, will continue working on a new kind of compounds, non-competitive pharmacology chaperones identified through the innovative platform of SEE’Tx. The compounds developed by Minoryz have a higher potential compared to previous generations of pharmacological chaperones. The most advanced projects of this platform are GM1 glangliosidosis and type B Morquio syndrome, both rare diseases.

Minoryx Therapeutics was created in 2011, with the support and consultancy of Bosch i Gimpera Foundation, by Marc Martinell, Xavier Barril and Joan Aymamí. Their objective was to develop drugs to treat rare or minority diseases, a set of severe diseases that affect especially children and teenagers. The 90% of the cases don’t have healing treatments, so there is a medical and social need which is not covered. Minoryx Therapeutics works on making therapies to improve the quality and life expectancy of the affected people. This is partly done from a technological platform that adds a developed technology to the University of Barcelona by Xavier Barril.

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream